What Lighthouse Pharma does

Lighthouse Pharmaceuticals, Inc. (DBA Lighthouse Pharma) is a clinical-stage biopharmaceutical company developing small-molecule gingipain inhibitors, with its lead asset LHP588 in mid-stage development for Alzheimer's disease. Founded in 2022 and headquartered on the Buck Institute for Research on Aging campus in Novato, California, the company targets lysine-gingipain (Kgp), a key virulence protease produced by Porphyromonas gingivalis, which has been implicated as a contributing driver of neurodegeneration. LHP588 is an oral, once-daily, brain-penetrant small molecule evaluated in the Phase 2 SPRING trial (NCT06847321), a 300-patient, randomized, double-blind, placebo-controlled study in P. gingivalis-positive mild-to-moderate Alzheimer's patients identified via saliva-based P. gingivalis testing and plasma p-tau217 biomarker screening. The program is supported by a $49.2 million National Institute on Aging grant (Award R01AG088524) and is built on the biological and clinical rationale established by the predecessor compound atuzaginstat, whose Phase 2/3 subgroup analysis showed 57% slowing of decline on ADAS-Cog in P. gingivalis-positive patients.

The company's platform comprises an internal library of potent, selective protease inhibitors positioned for additional indications including cardiovascular disease, atherosclerosis, orodigestive cancer, and periodontal disease. A proprietary canine periodontal compound from the same chemistry has been out-licensed exclusively to Phibro Animal Health Corporation (Nasdaq: PAHC) for global development, manufacturing, and commercialization in companion animals, providing Lighthouse with optionality on veterinary royalties without internal commercial build-out. Lighthouse Pharma is privately held (founded 2022, 1-10 employees), led by co-founder and CEO Casey Lynch and co-founder/CSO Stephen Dominy, with Dr. Michael J. Detke as Chief Medical Officer and Marwan Sabbagh, M.D. chairing its Clinical Advisory Board. The company closed a $12 million Series A financing led by Double Point Ventures in April 2026 and earlier raised a $49.2M NIA grant in August 2025; it remains pre-revenue with capital deployment focused on Phase 2 clinical execution and pipeline expansion.

Name

Lighthouse Pharma

Legal name

Lighthouse Pharmaceuticals, Inc.

Website

https://lighthousepharma.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Lighthouse Pharma is a clinical-stage biopharmaceutical company developing oral, brain-penetrant small-molecule gingipain inhibitors, with lead asset LHP588 in a 300-patient Phase 2 trial for P. gingivalis-positive mild-to-moderate Alzheimer's disease, supported by a $49.2M NIA grant and a $12M Series A.

Ownership category

akta.pro rank

Product category

Clinical-stage biopharmaceuticals — Alzheimer's disease therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Lead Optimization & Preclinical Candidate Selection (HLAIALAB)

akta.pro secondary industry

In Vivo Pharmacology (Efficacy/PD Models) (HLAGAFAA)

Keywords

• Gingipain inhibitors
• Alzheimer's therapeutics
• Clinical-stage biotechnology
• Small molecule drug development
• Neurodegenerative disease treatment

Headquarters

HQ city

Novato

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pre-revenue clinical development: Company is currently pre-revenue, funding Phase 2 clinical development of LHP588 through equity capital and non-dilutive grant funding rather than commercial product sales.
2. Licensing royalties (animal health): Out-licensed canine periodontal program to Phibro Animal Health Corporation under a licensing agreement; financial terms undisclosed, future royalty/milestone revenue potential.
3. Non-dilutive grant funding (NIA): $49.2M grant from the National Institute on Aging to support the Phase 2 program for LHP588 in P. gingivalis-positive mild-to-moderate Alzheimer's disease.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels4 records

Core offering

Lighthouse Pharma is a clinical-stage biopharmaceutical company developing small-molecule gingipain inhibitors, with lead asset LHP588 — an oral, once-daily, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to neutralize the virulence proteases of Porphyromonas gingivalis. The lead program is being evaluated in the Phase 2 SPRING trial in P. gingivalis-positive mild-to-moderate Alzheimer's disease, while a canine periodontal compound from the same platform has been out-licensed to Phibro Animal Health and additional discovery-stage protease inhibitors target cardiovascular disease, atherosclerosis, and orodigestive cancer.

Product overview

Lighthouse Pharma is a single-platform clinical-stage biopharmaceutical company built around a proprietary gingipain (lysine-gingipain / Kgp) inhibitor chemistry. Its lead asset, the next-generation oral small-molecule LHP588, is being evaluated in the Phase 2 SPRING trial for P. gingivalis-positive mild to moderate Alzheimer's disease, while the company's broader library of potent protease inhibitors supports additional discovery-stage programs in periodontal disease, cardiovascular disease, and orodigestive cancer. The first-generation compound atuzaginstat serves as a clinical proof-of-concept predecessor, and a separate canine periodontal compound from the same gingipain-inhibitor platform has been out-licensed exclusively to Phibro Animal Health for companion-animal use.

Differentiator

Problem solved

Functional benefit

Products and services

• LHP588 (oral Kgp inhibitor lead asset) Next-generation, orally bioavailable, brain-penetrant lysine-gingipain (Kgp) inhibitor small molecule designed to selectively block the key virulence factor of Porphyromonas gingivalis, reducing bacterial toxicity and load. Investigational therapeutic for P. gingivalis-positive mild-to-moderate Alzheimer's disease; targets neurology / memory-care prescribers, hospital formularies, and the 6M+ U.S. AD population.
• Library of Potent Protease (Gingipain) Inhibitors Internal discovery-stage library of potent, selective gingipain inhibitors being progressed for additional indications beyond Alzheimer's disease, including periodontal disease, cardiovascular disease/atherosclerosis, and orodigestive cancer. Functions as the underlying chemistry platform for the company's pipeline.
• Canine Periodontal Health Compound (licensed to Phibro Animal Health) Proprietary gingipain-inhibitor compound developed by Lighthouse Pharma for canine periodontal care, out-licensed exclusively to Phibro Animal Health Corporation for global development, manufacturing, and commercialization in companion animals. Target buyer: animal-health pharmaceutical companies; end users are veterinary clinics and dog owners.

Quantifiable outcome

• $49.2M NIA grant awarded to support the LHP588 Phase 2 program in P. gingivalis-positive mild-to-moderate Alzheimer's disease.
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core commercial partner, core scientific partner and awareness partner.

• Phibro Animal Health Corporationcore commercial partnerOEM/ Whitelabel/ Licensing PartnerLicensing agreement covering Lighthouse Pharma's gingipain inhibitor program for canine periodontal health, extending the platform into veterinary indications through Phibro's animal-health commercial infrastructure. Financial terms undisclosed.
• Buck Institute for Research on Agingcore scientific partnerStrategic or Co-development PartnerLighthouse Pharma relocated its corporate headquarters to the Buck Institute campus in Novato, California on November 17, 2025, embedding the company within a leading aging-research institute and enabling close scientific collaboration.
• BrightFocus Foundationawareness partnerGTM or Marketing PartnerCo-marketing and disease-awareness partner referenced in connection with webinars/events supporting Lighthouse Pharma's mission in Alzheimer's and aging research.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Cortexyme: Cortexyme originally developed atuzaginstat, the first-generation gingipain inhibitor that Lighthouse's LHP588 program is built on, making it the most directly comparable peer in mechanism, indication, and clinical-stage focus.
• Cassava Sciences: Cassava Sciences is a clinical-stage biotech developing simufilam for Alzheimer's disease, sharing Lighthouse's profile as a small, mechanism-differentiated, late-stage AD biotech pursuing a non-amyloid hypothesis.
• Anavex Life Sciences: Anavex is a clinical-stage biotech developing blarcamesine for Alzheimer's disease and other neurodegenerative indications, comparable as a small-cap, mechanism-differentiated CNS biotech at a similar development stage.
• AC Immune: AC Immune is a clinical-stage biotech developing vaccines and small molecules against neurodegenerative diseases including Alzheimer's, with overlapping target biology and a similar biomarker-enrichment strategy.

Emerging players

• BioVie: BioVie is developing NE3107 for Alzheimer's and Parkinson's disease, positioning it as a peer clinical-stage biotech pursuing a non-amyloid, inflammation-targeted approach in neurodegeneration.

Broad incumbents

• Prothena: Prothena is a clinical-to-commercial biotech with a broader neurodegenerative pipeline (Alzheimer's, Parkinson's, ATTR amyloidosis), comparable as a more advanced, broader neurodegeneration specialist with overlapping target biology.
• Eisai: Eisai co-developed lecanemab (Leqembi) with Biogen, the first anti-amyloid biologic approved for early Alzheimer's, making it a major incumbent competitor defining the standard of care Lighthouse's LHP588 would need to beat or complement.
• Biogen: Biogen co-markets Leqembi and has a broad Alzheimer's and neuroscience pipeline, making it the dominant commercial incumbent whose installed anti-amyloid franchise Lighthouse would compete against in mild-to-moderate AD.
• Eli Lilly: Lilly markets donanemab (Kisunla) and is developing next-generation AD therapies, making it the largest commercial competitor defining the efficacy, safety, and pricing benchmark LHP588 must surpass.

Others

• Phibro Animal Health: Phibro is Lighthouse's exclusive licensing partner for the canine periodontal gingipain-inhibitor program and a strategic commercialization channel for the platform's veterinary applications.

Market position

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lighthouse Pharma